Does which type of progesterone or progestin I take affect my breast cancer risk?

Multiple large observational studies agree the choice of progestogen matters and that micronized progesterone and dydrogesterone sit at the more favorable end of the risk range, while medroxyprogesterone acetate and norethisterone sit at the less favorable end.

But the studies disagree on the details: a French cohort study found essentially no increased breast cancer risk with estrogen plus micronized progesterone specifically, compared with clearly increased risk for other progestogens, while a larger UK dataset found progesterone still carried somewhat elevated risk, just less than other options, with dydrogesterone lowest. Every one of these studies is observational, not a randomized trial, and there will almost certainly never be a randomized trial comparing progestogens with breast cancer as an endpoint, because the sample size and duration required are prohibitive. This is described as likely to remain permanently unresolved at the highest evidence level.

What to know about this answer

This is described as one of the two central live debates in this whole topic: does the progestogen genuinely change breast cancer risk by a meaningful amount, or is the difference real in direction but overstated in size because of how differently the women taking each progestogen were selected in the first place.

What the research shows, and which source each finding rests on

In the French E3N cohort (80,377 postmenopausal women, 2,354 invasive breast cancers), compared with never use: estrogen alone had relative risk 1.29; estrogen plus progesterone had relative risk 1.00 (95% CI 0.83-1.22); estrogen plus dydrogesterone had relative risk 1.16; estrogen plus other progestagens had relative risk 1.69

C [1]

In the UK QResearch/CPRD dataset (98,611 breast cancer cases, 457,498 controls), norethisterone carried the highest adjusted odds ratio among progestogens at 1.88, and dydrogesterone the lowest at 1.24; combined estrogen-progestogen therapy overall was 1.79 and estrogen-only was 1.15; the authors' absolute translation was 3 to 8 extra breast cancer cases per 10,000 woman-years for recent estrogen-only users and 9 to 36 for estrogen-progestogen users

C [2]

The E3N follow-up found long-term current use of estrogen with a progestagen other than progesterone or dydrogesterone carried a hazard ratio of 2.02, falling to 1.36 within 5 years of stopping and 1.34 at 5-10 years, suggesting residual but declining excess risk after cessation, restricted to long-term users

C [3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Yes, substantially: micronized progesterone and dydrogesterone are meaningfully safer

Several clinicians in the field, most European menopause societies, and the prevailing view in current clinical practice

The French cohort found essentially no increased risk with progesterone specifically, the UK dataset independently found a consistent gradient with dydrogesterone and progesterone-adjacent options at the lower end, and the WHI comparison of estrogen alone versus estrogen plus medroxyprogesterone acetate showed the excess breast cancer signal tracked the arm containing the synthetic progestin, not the estrogen.

C [1]C [2]

The difference is real in direction but the magnitude is overstated, and breast-neutral is not supportable

Guideline bodies that decline to make progestogen-specific safety claims, including UK guidance that does not endorse micronized progesterone as breast-safe

The larger UK dataset found combined therapy elevated across the board, with dydrogesterone still at 1.24 rather than a true null; the French cohort's null result for micronized progesterone has never been reproduced with the same magnitude, and all this data is observational and vulnerable to confounding by indication, since the women prescribed micronized progesterone were plausibly systematically different, healthier, younger, or better informed, than those prescribed other progestogens. A relative risk of 1.00 with a confidence interval running to 1.22 is compatible with as much as a 22% increase, so reporting it as flatly no risk misreads the confidence interval.

C [2]C [3]

What would settle it: A randomized trial of estradiol plus micronized progesterone versus estradiol plus a synthetic progestin with breast cancer as the primary endpoint would settle it, but this will almost certainly never be run given the prohibitive required sample size and duration; this debate is likely to remain permanently unresolved at the highest evidence level.

What is really going on here

Is a claim that micronized progesterone is breast neutral treating a relative risk near 1.0 as proof of zero risk, when the confidence interval may still be compatible with meaningfully elevated risk?
Could the women who chose micronized progesterone in these studies have been systematically different, healthier, younger, better informed, from women who took other progestogens, in a way that could explain part of the difference?
Is a progestogen-risk claim being drawn from the French cohort, the UK dataset, or both, and do their exact estimates agree?

Questions for your doctor

Which specific progestogen would I be taking, and where does it fall in the observational risk data?
Given that no randomized trial exists comparing progestogens for breast cancer risk, how confident should I be in a specific progestogen's safety profile?
Does my personal or family breast cancer history change which progestogen makes sense for me?
If I'm currently on a progestin other than micronized progesterone or dydrogesterone, is there a reason to consider switching?

Questions with no answer yet

Is micronized progesterone genuinely breast-neutral, or does its relative-risk estimate simply have too wide a confidence interval to rule out a real, moderate increase in risk?

Partly studied

What is known: The French cohort found a relative risk of 1.00 for estrogen plus micronized progesterone, but the confidence interval, 0.83 to 1.22, is compatible with as much as a 22% increase in risk; a larger UK dataset did not reproduce a true null for the progesterone-adjacent option it studied, finding dydrogesterone lowest at 1.24 rather than 1.00.

What would test it: A randomized trial of estradiol plus micronized progesterone versus estradiol plus a synthetic progestin with breast cancer as the primary endpoint would settle it, but the field expects this will almost certainly never be run given the required sample size and duration.

How much of the favorable risk profile seen with micronized progesterone in the French cohort reflects the drug itself, versus the fact that women prescribed micronized progesterone may have been systematically healthier, younger, or better informed than women prescribed other progestogens?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The observational data are vulnerable to confounding by indication, since the women prescribed micronized progesterone were plausibly a different population than those prescribed other progestogens; no study has directly measured or adjusted for this specific selection pattern.

What would test it: A study designed specifically to measure and adjust for prescribing-pattern differences between progesterone and other progestogen users, or, ideally, the randomized trial named above.

Sources

1.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103-111. · Observational study
2.Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873. · Observational study
3.Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.Fournier A, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145(2):535-543. · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping